Labiotech.eu

Podcast 1 Dec 2023

Ipsen drug gives hope for liver disease patients

On the podcast this week, we are looking at recent advances in treating certain liver diseases. Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen, and she discusses a breakthrough treatment for primary biliary cholangitis and cholestatic liver disease. What is primary biliary cholangitis? Primary biliary […]

December 1, 2023

In Depth 30 Nov 2023

Could an Alzheimer’s vaccine make treatment more affordable?

Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]

November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter

Opinion 29 Nov 2023

Redefining drug development: the trailblazing evolution of the pharmaceutical industry

Drug discovery and development is a long, costly, and high-risk process that takes over 10 to 15 years with an average cost of over $1 to $2 billion for each new drug to be approved for clinical use. For any pharmaceutical company or academic institution, it is a big achievement to advance a drug candidate […]

November 29, 2023 - 9 minutesmins - By External Contributor

Best in Biotech 28 Nov 2023

Five companies shaping Texas’ growing biotech hubs

Thanks to the U.S. government’s ambitious plans to advance American biotech and biomanufacturing, Texas’ life sciences hubs, particularly in Dallas and Houston, are now one of many in the country that are currently thriving. In this article, we take a closer look at several biotech companies in Texas taking advantage of the additional investment in […]

November 28, 2023 - 8 minutesmins - By Willow Shah-Neville

In Depth 27 Nov 2023

How are R&D Tax Incentives shaping Australia’s biotech future?

Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […]

November 27, 2023 - 5 minutesmins - By Jules Adam

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round Chinese company Viva Biotech closed a funding round worth $210 […]

November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter

Podcast 24 Nov 2023

Company exits stealth to launch molecular gates

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of Gate Bioscience. Gate Bioscience is a U.S.-based biotechnology company creating a new class of medicines called Molecular Gates. Founded in 2021, Gate is emerging from stealth with a novel scientific platform and $60 million in Series A funding […]

November 24, 2023

In Depth 23 Nov 2023

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]

November 23, 2023 - 5 minutesmins - By Jules Adam

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]

November 22, 2023 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 21 Nov 2023

Beyond insulin: six cutting-edge diabetes biotech companies you should know about

As we predicted last year, the diabetes market is booming, particularly after the incredible success of new diabetes drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. There are now several diabetes biotech companies that are garnering attention, all with their own innovative solutions to tackling both type 1 and type 2 diabetes. The prevalence […]

November 21, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 20 Nov 2023

M&As: what’s up with the ADC buying spree?

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]

November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 17 Nov 2023

With $700 million Q3 rise, U.K. biotech spearheads European recovery

The U.K.’s biotechnology landscape has witnessed an impressive surge in funding, clocking a robust £563 million ($700 million) in venture capital and public financings in the third quarter of 2023, according to Biotech Finance. This achievement marks a staggering 48% increase from the previous quarter and sets a formidable pace that is already on track […]

November 17, 2023 - 4 minutesmins - By Jules Adam

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ipsen drug gives hope for liver disease patients

Could an Alzheimer’s vaccine make treatment more affordable?

Redefining drug development: the trailblazing evolution of the pharmaceutical industry

Five companies shaping Texas’ growing biotech hubs

How are R&D Tax Incentives shaping Australia’s biotech future?

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

Company exits stealth to launch molecular gates

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Beyond insulin: six cutting-edge diabetes biotech companies you should know about

M&As: what’s up with the ADC buying spree?

With $700 million Q3 rise, U.K. biotech spearheads European recovery

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!